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Abstract. For the purpose of definition of an adequate marker of a power exchange condition at 
the experimental ischemia of the myocardium due introduction of metabolic drugs, the 
experimental research on 60 rats-males of Wistar line has been spent. At experimental myocardial 
ischemia it has been found out energy-saving  effects of trimetazidine, cytoflavin, meldonium, 
phosphocreatine, which were reached by different ways and in different degree. The indicator of 
ATP concentration  in blood or erythrocytes closely correlated with the level of ATP in 
myocardial homogenates and with activity of mitochondrial heart enzymes – succinate 
dehydrogenase, citrate synthase, pyruvate dehydrogenase. Thus, this indicator can be 
recommended to study to assess the effectiveness of cardiocytoprotectors as the most appropriate 
marker of their energy-saving effect. 
Keywords: ATP, myocardial metabolism, cardiocytoprotection, energy-saving effect, metabolic 
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Introduction 
The high indicators of prevalence and death rate 
from coronary heart disease (CHD), despite the 
accepted standards of pharmacotherapy, cause necessity 
of modernisation of the accepted schemes of treatment 
[1, 2]. One of the promising directions of improving the 
pharmacotherapy of CHD considered 
cardiocytoprotection [3, 4, 5, 6]. Metabolic-line drugs 
are widely used by doctors of the countries in post-
Soviet space as ones that enhance the patients’ life 
quality, whereas in Europe they are administered not 
more than in 1% of cases due to the lack of evidence of 
their impact on the patients’ life expectancy [7]. One of 
the obstacles of overcoming the doubts of doctors in the 
effectiveness of the destination cardiocytoprotectors is 
absence of adequate methods of myocardium 
metabolism estimation in view of inaccessibility and 
ethical impossibility of performance of researches on 
human heart tissue. 
The purpose of the present research was 
definition of an adequate marker of a myocardium 
power exchange condition at an experimental 
ischemia of a myocardium due the introduction of 
metabolic drugs. 
Materials and methods of the research 
For achievement of the purpose of work the 
experimental research which object were 60 rats-
males of Wistar line aged by 10 months, which 
contained in standard conditions of vivarium, has 
been executed. The following groups of animals were 
used: 1) intact rats (n=10); 2) rats with an 
experimental ischemia of a myocardium (n=10); 
3) rats with an experimental ischemia of a
myocardium entered trimetazidine (n=10); 4) rats 
with an experimental ischemia of a myocardium 
entered meldonium (n=10); 5) rats with an 
experimental ischemia of a myocardium entered 
cytoflavin (n=10); 6) rats with an experimental 
ischemia of a myocardium entered phosphocreatine 
(n=10). Age of animals was chosen from a position 
of conformity of 10-month's rats – to middle age of 
human being. The choice of metabolic drugs spent 
from positions of their influence on various links of 
the power exchange of cardiomyocytes.  
Modelling of an ischemia of a myocardium has 
been made on the method described by Gaman D.V. 
(2011) [8]: daily within 7 days subcutaneously the rats 
were entered 0,1 ml of 0,1 % adrenaline solution. A 
dose of medical drugs, entered with the therapeutic 
purpose, was counted under formula of Rybolovlev J.R. 
(1979), it has been made 1) for trimetazidine (a pure 
solid of firm «Sigma Aldrich») – 0,5mg/100g rats in 2 
ml of 0,9% NaCl solution intragastric 2 times a day, 
that is equivalent to a recommended dose of 
trimetazidine for a human (35 mg 2 times a day per os); 
2) for meldonium (Мildronate of  "Grindex" firms,
Рус.
 
Eng.
 DOI: 10.18413/2500-235X -2016-2-3-58-62
Kukes V. G., Gorbach T. V., Romashchenko O. V., Rumbesht V. V. АТP as the marker of power 
exchange condition at the experimental ischemia of the myocardium due to metabolic drugs 
introduction. Research result: pharmacology and clinical pharmacology. Vol. 2, №3 (2016): 58-62. 
59 
RESEARCH RESULT:  
PHARMACOLOGY AND CLINICAL PHARMACOLOGY 
Latvia) – 0,03ml/100g rats in 1,5 ml of 0,9 % NaCl 
solution intravenously 1 time a day, that is equivalent to 
the recommended dose for a human (5 ml intravenously 
1 time a day; 3) for cytoflavin – 0,07ml/100g rats in 1,5 
ml of 0,9 % NaCl solution intravenously 1 time a day, 
that is equivalent to the recommended dose for a human 
(10 ml intravenously in 200 ml of  0,9 % NaCl solution 
1 time a day); 4) for phosphocreatine – 13mg/100g rats 
in 2 ml of 0,9 % NaCl solution intravenously 1 time a 
day, that is equivalent to the recommended dose for a 
human (2g/days intravenously of a medicine 
"Neotone").  
The animals were deduced from experiment in 
10 days after introduction of medicines by 
decapitation. The heart was perfused with a cooled 
solution of 0.9% NaCl. Preparation of myocardial 
homogenates and isolation of mitochondria was 
produced by the method described of M.V. Egorova, 
S.A. Afanasyev [9]. The erythrocytes were isolated 
from heparinized blood by centrifugation. The 
washed erythrocytes were used for determination of  
2,3-diphosphoglycerat (2,3-DPG) and free 
nucleotides (ATP and ADP) (N.P. Meshkova, S.E. 
Severin, 1979). The content of ATP and ADP was 
measured in the serum of blood (I.S. Mranova, 1975). 
The activity of succinate dehydrogenase (SDH), 
citrate synthase (CS) and pyruvate dehydrogenase 
(PDH) was investigated in the myocardial 
mitochondria. The level of ATP was determined in 
myocardial homogenate (M.I. Prochorova, 1982). 
The data were treated by variation statistics with 
arithmetic mean values and their errors, correlation 
analysis, assessment of significant differences in the 
student t-test using the software "Microsoft Excel 
2000" and "SPSS for Windows 11.0". 
Results and their discussion 
At modelling of the ischemia of a myocardium 
of 10 months rats a significant increase in 2,3-DPG 
and a decrease in ATP concentration in erythrocytes 
was found, suggesting the development of tissue 
hypoxia and energy deficiency (Table 1). At the 
mitochondria a significant decrease in the activity of 
studied enzymes – SDG, CS and PDG was found, 
which indicates a decrease in the intensity of 
oxidative phosphorylation and oxidative 
decarboxylation of pyruvate. The consequence of this 
fact a significant decrease in the concentration of 
ATP in myocardial homogenates was observed. 
At the animal experiments the effectiveness of all 
4 metabolic drugs due to chronic myocardial ischemia 
have been studied. We found significant differences in 
the mechanisms of action of each of them. 
We considered the main indicator of energy 
saving effect of metabolic drugs the ATP levels in 
myocardial homogenates, which reflects the amount 
of ATP in cardiomyocytes. Introduction of 
trimetazidine, cytoflavin and phosphocreatine 
increased ATP concentration in cardiomyocytes, but 
without reaching the level of intact rats. Introduction 
of meldonium led to the recovery of the amount of 
ATP in the heart homogenates to the level of the 
intact rats, without excessive accumulation of 
nucleotides, which in our opinion, indicates the 
absence of doping properties of the drug. 
ATP levels in serum and red blood cells due to 
introduction of metabolic correctors have similar 
dynamics, as reflected in Table 1, and indirectly 
confirmed by correlation analysis. Positive 
correlations were found between the concentration of 
ATP in myocardial homogenates and blood serum (r 
= 0,66, p <0,0001), in red blood cells (r = 0,66, p 
<0,0001). ATP levels in myocardial homogenate is 
also positively correlated with the activity of 
mitochondrial enzymes – succinate dehydrogenase (r 
= 0,67, p <0,0001), citrate synthase (r = 0,65, p 
<0,0001) and pyruvate dehydrogenase (r = 0,75 , p 
<0,0001). There is an inverse relationship between 
ATP concentration in the myocardium and 2,3DPG 
level in red blood cells (r = -0,33, p <0,01). Thus, the 
more active oxidation-reduction reactions take place 
in the mitochondria, the higher  levels of ATP detect 
in myocardial homogenates , blood serum and 
erythrocytes with the lower level of tissue hypoxia. 
So that, in terms of ATP concentrations in serum and 
/ or erythrocytes it can be indirectly judged the 
content of ATP in the myocardium and the intensity 
of the oxidation-reduction reactions taking place in 
the mitochondria of the cardiomyocytes. 
We studied the effect of metabolic correctors on 
the activity of mitochondrial enzymes in comparative 
aspect. Thus, the succinate dehydrogenase activity in 
experimental myocardial ischemia was significantly 
reduced. Introduction of cytoflavin and  meldonium 
led to partial activation of SDH, but not to the level 
of the intact rats, administration of trimetazidine and 
phosphocreatine was accompanied by decreased 
activity of this Krebs cycle enzyme (Table 1). 
Activity of citrate synthase in experimental 
myocardial ischemia was significantly reduced. 
Introduction of  trimetazidine, meldonium and 
cytoflavin led to a slight increase in CS activity in 
mitochondria, while the introduction of 
phosphocreatine was accompanied by inactivation 
citrate synthase in the mitochondria of rats. 
Pyruvate dehydrogenase activity in 
mitochondria of cardiomyocytes in experimental 
myocardial ischemia was significantly reduced. 
Introduction of cytoflavin to the animals was 
contributed to increase the activity of PDH to the 
level of the intact rats, administration of 
phosphocreatine contributed to a slight increase in 
the activity of PDH, while trimetazidine had no 
significant effect on the activity of this enzyme. 
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Table 1 
Indicators of myocardial metabolism in 10 months rats in normal, at experimental myocardial ischemia and on the background 
of metabolic correctors (M ± m) 
Indicators 
Intact rats 
of 10 months, n=10 
Rats with 
myocardial 
ischemia, 
n=10 
Rats with 
myocardial 
ischemia + 
cytoflavin, 
n=10 
Rats with 
myocardial 
ischemia + 
trimetazidine, 
n=10 
Rats with 
myocardial 
ischemia + 
meldonium, 
n=10 
Rats with 
myocardial 
ischemia + 
phosphocreatine, 
n=10 
E
ry
th
ro
cy
te
s ATP, mkmol/l 664,54±14,49 ΔΔ## 594,44±5,75** 582,47±5,24** 587,05±6,40** 638,88±14,96Δ 589,28±5,43** 
ADP, mkmol/l 315,11±8,78 330,53±16,05 316,05±3,01 323,57±5,40 319,27±7,51 328,86±2,93 
2,3DPG, mkmol/l 4,82±0,29 ΔΔ## 7,21±0,32** 6,84±0,15** 6,12±0,19 Δ 5,70±0,18* ΔΔ 6,69±0,21** 
S
er
u
m
 
o
f 
b
lo
o
d
 
ATP, mkmol/l 200,08±3,47 ΔΔ## 162,81±4,57**# 177,70±2,15**Δ 171,81±1,61** 192,32±5,36 ΔΔ 192,02±4,76ΔΔ 
ADP, mkmol/l 75,92±1,58## 79,31±1,13## 91,21±0,79** ΔΔ 85,00±3,22* 77,33±2,29 90,91±1,56**ΔΔ 
M
it
o
ch
o
n
d
ri
a 
SDH, 
nmol/min·mg 
17,82±1,10 ΔΔ## 11,83±0,47**# 13,45±0,47**Δ 10,77±0,68**ΔΔ 13,68±0,65* 10,12±0,29**Δ 
CS, nmol/min·mg 3,94±0,23 ΔΔ# 2,38±0,21**# 3,21±0,20*Δ 3,08±0,27** 3,12±0,10*Δ 2,00±0,08** 
PDH, 
mkmolNAD/min·
mg 
31,04±0,89 ΔΔ 21,68±0,90**## 31,34±0,73 ΔΔ 22,32±0,57** 27,30±0,45** ΔΔ 24,45±0,34** Δ 
ATP in 
myocardial 
homogenate, 
mkmol/l 
3,08±0,24 ΔΔ# 1,18±0,08**## 2,09±0,16* ΔΔ 2,00±0,05**ΔΔ 3,16±0,09 ΔΔ 1,96±0,08**ΔΔ 
Note. ATP – adenosine triphosphate, ADP – adenosine diphosphate, 2,3DPG – 2,3-diphosphoglycerat, SDH – succinate dehydrogenase, CS – citrate 
synthase, PDH – pyruvate dehydrogenase. The significance of differences: *p<0,05; ** p<0,01 as compared to the intact rat; Δ p<0,05; ΔΔ p<0,01 as 
compared to the group of "myocardial ischemia"; # p<0,05; ## p<0,01 as compared to the group of "myocardial ischemia + cytoflavin"; 
 $
p<0,05; 
$$
p<0,01 as 
compared to the group of "myocardial ischemia + meldonium";
!
 p<0,05; 
!!
 p<0,01 as compared to the group of "myocardial ischemia + phosphocreatine". 
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We found a strong direct correlations between all 
studied mitochondrial enzymes: SDH and CS (r = 0,75, 
p <0,0001), SDH and PDH (r = 0,70, p <0,0001), the 
CS and SDH (r = 0,74, p <0,0001), and between them 
and the ATP levels in the myocardium, erythrocytes 
and blood serum, what has been said above. 
Our findings, firstly, confirm the presence of 
energy-saving effect in all we have studied metabolic 
correctors – trimetazidine, cytoflavin, 
phosphocreatine and meldonium, secondly, they 
show that the achievement of energy economization 
within cardiomyocytes occurs in different ways and 
to varying degrees because of different mechanisms 
of action. The studied results are consistent with 
published data [10, 11, 12] 
Really, trimetazidine contributes switch in 
energy metabolism from fatty acid oxidation to 
glucose oxidation by inhibiting acetyl-CoA 
acyltransferase, a key enzyme in fatty acid oxidation 
in mitochondria [13, 14]; cytoflavin contains four 
components (succinic acid, riboxinum, nicotinamide 
and riboflavin), each of which contributes to the 
stimulation of Krebs cycle inside the mitochondria 
[15, 16]; phosphocreatine is an exogenous source of 
substrate phosphorylation reacti 
+ons inside cardiomyocytes [17]; meldonium 
blocks synthesis of carnitine, transporter of fatty 
acids from the mitochondria into the cytosol, thereby 
switches the energy exchange from lipid to 
carbohydrate types, meldonium also stimulates the 
synthesis of nitric oxide [17, 18]. 
The most important result of our research we 
consider found out the strong correlations between 
the concentration of ATP into the miocardial 
homogenate and the level of this nucleotide in serum 
and red blood cells, which are also linked with the 
activity of cardiomyocytes’ mitochondrial enzymes. 
This fact is the basis to offer for use in clinical 
practice index of ATP concentration in blood serum 
or red blood cells as the most adequate and accessible 
marker of energy metabolism state in 
cardiomyocytes, and in the case of the definition of 
this indicator during the treatment of patients with 
cardiocytoprotectors it can be judged the energy-
saving effect of the latest . 
Conclusions 
1. ATP concentration in serum or red blood
cells is the most appropriate measure of the energy 
metabolism in the heart muscle due to the close 
correlation with the level of ATP in myocardial 
homogenates, and the activity of mitochondrial 
enzymes of the heart – succinate dehydrogenase, 
citrate synthase, pyruvate dehydrogenase. 
2. In the experimental myocardial ischemia it
has been detected energy-saving effects of 
trimetazidine, cytoflavin, phosphocreatine and 
meldonium, which were achieved in different ways 
and to varying degrees. 
3. Introduction of meldonium to the animals
with experimental myocardial ischemia resulted in 
recovery amount of ATP in heart homogenate to the 
level of intact rats without excessive accumulation of 
this nucleotide, indicating a lack of doping properties 
of the drug. 
4. To assess the effectiveness of 
cardiocytoprotectors in complex treatment of patients 
with cardiac pathology, the study of ATP 
concentration in erythrocytes and serum can be 
recommended during the treatment as the most 
appropriate marker of their energy-saving effect. 
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